Research / Clinical Summary

Edward Ball, MD Professor, Medicine Hematologic Malignancies Program Contact by Email Visit the Website

Other Positions:
Chief, Division of Blood & Marrow Transplantation
Co-Program Leader, Hematological Malignancies Program

Dr. Edward Ball’s research has been focused on the development of monoclonal antibody targeted immunotherapy, and its translation to the treatment of patients with malignancy. He has produced a large number of monoclonal antibodies to myeloid-associated antigens expressed on myeloid leukemia cells. These antibodies have been used clinically for the diagnosis and treatment of acute myeloid leukemia (AML).

He has conducted a multi-center clinical trial using antibody-mediated purging using the AML cells from the marrow of patients with leukemia prior to transplantation, after high dose chemotherapy. Dr. Ball has developed in vivo therapeutics using first an anti-CD 15 antibody and, later with bispecific antibodies.

He is currently conducting a phase I/II clinical trial testing the ability of 5-azacytidine to augment the efficacy of an anti-CD33 drug conjugate (Mylotarg) that is based on his laboratory research. Another line of investigation involves using bifunctional antibody targetting gastrin-releasing peptide receptors on adenocarcinoma cells including prostate, breast, and lung cancers. This antibody triggers normal leukocyte ADCC against gastrin-releasing peptide receptor-positive cancer cells.

Dr. Ball also leads several clinical trials that are designed to improve the outcomes of hematopoietic stem cell transplantation.

Update Summary via ONcLINE (password required)
Click here to request a new or forgotten password